US2021330718A1PendingUtilityA1

Composition and methods for treating cancer and immune disorders using veillonella bacteria

56
Assignee: EVELO BIOSCIENCES INCPriority: Feb 6, 2018Filed: Jul 6, 2021Published: Oct 28, 2021
Est. expiryFeb 6, 2038(~11.6 yrs left)· nominal 20-yr term from priority
Inventors:Brian GoodmanBaudauna BoseChristopher J. H. DavittMaria SizoveSofia M.R. CarltonAndrea ItanoHolly PonichteraTaylor A. CormackKritika Ramani
A61P 37/02A61K 2300/00C12R 2001/01C12N 1/20Y02A50/30A61K 45/06A61P 37/06A61P 3/10C07K 16/2818C12M 47/12A61P 1/16A61P 35/00C12M 29/04A61K 39/0011A61K 2039/505C12N 1/205A61K 35/74C12M 47/10A61P 17/06A61P 19/02
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 161 . (canceled) 
     
     
         162 . A method of treating an immune disorder in a subject comprising orally administering to the subject a pharmaceutical composition comprising  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691) and a pharmaceutically acceptable carrier. 
     
     
         163 . The method of  claim 162 , wherein the  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691) and the pharmaceutically acceptable carrier are within an enteric coating. 
     
     
         164 . The method of  claim 162 , wherein the immune disorder is atopic dermatitis, psoriasis, or asthma. 
     
     
         165 . The method of  claim 162 , wherein at least 50% of the bacteria in the pharmaceutical composition are  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691). 
     
     
         166 . The method of  claim 162 , wherein at least 95% of the bacteria in the pharmaceutical composition are  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691). 
     
     
         167 . The method of  claim 162 , wherein at least 99% of the bacteria in the pharmaceutical composition are  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691). 
     
     
         168 . The method of  claim 162 , wherein the pharmaceutical composition comprises at least 1×10 6  colony forming units (CFUs) of  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691. 
     
     
         169 . The method of  claim 162 , wherein the pharmaceutical composition comprises live bacteria. 
     
     
         170 . The method of  claim 162 , wherein the pharmaceutical composition comprises killed bacteria. 
     
     
         171 . The method of  claim 162 , wherein the pharmaceutical composition comprises irradiated bacteria. 
     
     
         172 . The method of  claim 171 , wherein the irradiated bacteria comprises gamma irradiated bacteria. 
     
     
         173 . The method of  claim 163 , wherein the pharmaceutical composition is formulated as an enteric coated capsule. 
     
     
         174 . The method of  claim 163 , wherein the pharmaceutical composition is formulated as an enteric coated tablet. 
     
     
         175 . The method of  claim 163 , wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2. 
     
     
         176 . The method of  claim 163 , wherein the enteric coating is a coating for release in the ileum at a pH of about 7.2-7.2. 
     
     
         177 . The method of  claim 163 , wherein the enteric coating is a coating for release in the colon at a pH of about 5.6-7.2. 
     
     
         178 . The method of  claim 162 , wherein the  Veillonella parvula  Strain B (ATCC Accession Number PTA-125691) is freeze-dried. 
     
     
         179 . The method of claim  62 , wherein the method further comprises administering to the subject an additional therapeutic. 
     
     
         180 . The method of  claim 179 , wherein the additional therapeutic is an antibiotic. 
     
     
         181 . The method of  claim 179 , wherein the additional therapeutic is an anti-inflammatory agent.

Join the waitlist — get patent alerts

Track US2021330718A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.